This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Dermatology  • Dermatologic Disorders  • Herpes  • Alert me on articles by topic  Social Bookmarking   What's this?

John R. Mascola, MD

JAMA. 1999;282:379-380.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Most effective viral vaccines work, at least in part, by inducing antibodies capable of neutralizing the invading virus.^1-3 Examples among licensed human vaccines include measles, polio, rabies, influenza, hepatitis A, and hepatitis B vaccines.^4-6 Even for diseases such as chickenpox, in which cellular immunity is thought to control disease, administration of specific antibody (eg, varicella-zoster immune globulin) can protect against disease when administered up to 96 hours following viral exposure.⁷ Therefore, the report by Corey and colleagues in this issue of THE JOURNAL⁸ is perhaps surprising because a herpes simplex virus type 2 (HSV-2) vaccine that induced high levels of neutralizing antibodies did not protect against HSV-2 infection. The possible reasons for the apparent failure of this vaccine highlight the empirical nature of vaccine science, the limitations of preclinical and animal model studies, and the need for well-designed human efficacy trials.

Herpes simplex virus type 1 . . . [Full Text of this Article]

Author Affiliation: Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials
Lawrence Corey, Andria G. M. Langenberg, Rhoda Ashley, Rose E. Sekulovich, Allen E. Izu, John M. Douglas, Jr, H. Hunter Handsfield, Terri Warren, Lisa Marr, Stephen Tyring, Richard DiCarlo, Adaora A. Adimora, Peter Leone, Cornelia L. Dekker, Rae Lyn Burke, Wai Ping Leong, Stephen E. Straus, and for the Chiron HSV Vaccine Study Group
JAMA. 1999;282(4):331-340.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunologic Strategies for Herpes Vaccination
Friedman et al.
JAMA 2000;283:746-746.
FULL TEXT  

In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc
Lubinski et al.
JEM 1999;190:1637-1646.
ABSTRACT | FULL TEXT  

Herpes Vaccine Still Elusive
JWatch General 1999;1999:1-1.
FULL TEXT